Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.
Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-penicillamine. Although D-penicillamine-induced pemphigus has been not infrequently demonstrated, pemphigus associated with bucillamine was rarely reported. We describe a patient complicating pemphigus vulgaris after bucillamine treatment in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA overlap syndrome was diagnosed three years ago and bucillamine was administrated for 20 months. Skin lesions including erythematous flaccid blisters on her chest, axillae, and back were occurred and were compatible with pemphigus vulgaris by typical pathology. Withdrawal from bucillamine and prednisolone treatment made rapid improvement of pemphigus lesions.
Hur
Jin-Wuk
JW
Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Diseases, College of Medicine, Hanyang University, Seoul, Korea.
Lee
Chang-Woo
CW
Yoo
Dae-Hyun
DH
D000975:Antioxidants / Q000009:adverse effects*; D001168:Arthritis; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D001706:Biopsy; D003545:Cysteine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000473:pathology*; D017285:Polymyositis / Q000150:complications* / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D013577:Syndrome
D000975:Antioxidants; D003545:Cysteine; C026535:bucillamine